Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
ABOUT
UPCOMING EARNINGS
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-01-02 | Reverse | 1:30 |
| 2023-12-07 | Reverse | 1:15 |
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$2.66 ▼ DOWN 7.32% (−$0.21)About PAVmed Inc.
https://www.pavmed.com ↗PAVmed Inc. is a U.S.-based medical device company developing innovative products for diagnostics, minimally invasive treatments, and healthcare monitoring across various medical fields.
INDUSTRY
A PRODUCT PAVMED INC. IS KNOWN FOR
EsoGuard is a non-invasive test that analyzes esophageal DNA via the EsoCheck device to detect early esophageal precancer and cancer, with recent U.S. VA contract boosting its market presence.
PAVmed in 2025
PAVmed Announces 1-for-30 Reverse Stock Split to Address Nasdaq Listing Compliance
PAVmed Inc. announced it will execute a 1-for-30 reverse stock split of its common stock, effective January 2, 2026. This action was taken to regain compliance with the Nasdaq's $1.00 minimum bid price requirement, a move often seen as a measure to avoid delisting. The decision was approved by stockholders at a special meeting on December 5, 2025.
PAVmed Executes Major Financial Restructuring, Slashing Debt by 77% and Operating Expenses by 65% to Fortify Balance Sheet
In the first quarter of 2025, PAVmed completed a significant financial overhaul by restructuring $22.5 million of debt into preferred equity, reducing its debt obligations by 77%. This was coupled with a 65% reduction in non-GAAP operating expenses compared to the previous year, aimed at stabilizing the company's financial foundation and freeing up capital for its subsidiaries' growth initiatives.
RATINGS SNAPSHOT
Overall rating: C-
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 BNR | $15.67 | COMPARE |
 HSCS | $4.37 | COMPARE |
 ADVB | $6.47 | COMPARE |
 BMRA | $2.16 | COMPARE |
 APVO | $1.83 | COMPARE |
 TNON | $3.71 | COMPARE |
 SSKN | $0.01 | COMPARE |